Claims for Patent: 5,674,703

Summary for Patent: 5,674,703

Title:	Episomal vector systems and related methods
Abstract:	An episomal vector sytem and methods for use in gene therapy in humans and animals. The vector contains a papilloma virus origin of replication, a vector maintenance sequence, a first promoter transcriptionally linked to a therapeutic nucleic acid sequence, a second promoter transcriptionally linked to a papilloma virus E1 gene sequence, and a third promoter transcriptionally linked to a papilloma virus E2 gene sequence or an E1/E2 fusion gene. The vector is capable of episomal replication in human or animal cells.
Inventor(s):	Woo; Savio L. C. (Houston, TX), Nordloh; Peter W. (Burlington, IA), Stenlund; Arne (Cold Spring Harbor, NY)
Assignee:
Application Number:	08/161,286
Patent Claims:	1. An episomal vector system consisting essentially of: a papilloma virus origin of replication; a first promoter transcriptionally linked to a DNA sequence; a second promoter transcriptionally linked to a papilloma virus E1 gene sequence; and a third promoter transcriptionally linked to a papilloma virus E2 gene sequence; and wherein said second and third promoters and said E1 and E2 gene sequences are at least about 1 kb from said origin of replication, and said vector comprises no other papillomavirus coding sequences in addition to E1 and E2 gene sequences; and wherein said episomal vector system comprises one or more episomal vectors, each able to replicate as an episome. 2. The episomal vector system of claim 1 wherein said papilloma virus origin of replication and said first promoter transcriptionally linked to a DNA sequence are contained on a first episomal vector and said papilloma virus origin of replication, said second promoter transcriptionally linked to a papilloma virus E1 gene sequence and said third promoter transcriptionally linked to a papilloma virus E2 gene sequence are contained on a second episomal vector. 3. The episomal vector system of claim 1 wherein said papilloma virus origin of replication, said first promoter transcriptionally linked to a DNA sequence and either one of said second promoter transcriptionally linked to a papilloma virus E1 gene sequence or said third promoter transcriptionally linked to a papilloma virus E2 gene sequence are contained on a first episomal vector and said papilloma virus origin of replication, and the other one of said second promoter transcriptionally linked to a papilloma virus E1 gene sequence and said third promoter transcriptionally linked to a papilloma virus E2 gene sequence are contained on a second episomal vector. 4. The episomal vector system of claim 1, wherein said system consists of a single vector. 5. An episomal vector system consisting essentially of: a papilloma virus origin of replication; a vector maintenance sequence; a first promoter transcriptionally linked to a DNA sequence; a second promoter transcriptionally linked to an E1/E2 fusion gene sequence and no other papilloma virus coding sequences, said fusion gene sequence containing at least the trans-activation region of the E2 gene sequence; and wherein said second promoter and said E1/E2 fusion gene sequence is at least about 1 kb from said origin of replication; and wherein said episomal vector system comprises one or more episomal vectors, each able to replicate as an episome. 6. The episomal vector system of claim 5, wherein said system consists of a single vector. 7. The episomal vector system of claim 5 wherein said papilloma virus origin of replication and said first promoter transcriptionally linked to a DNA sequence are contained on a first episomal vector and said second promoter transcriptionally linked to an E1/E2 fusion gene sequence, said fusion gene sequence containing at least the trans-activation region of the E2 gene sequence, are contained on a second episomal vector. 8. The episomal vector system of claim 1-6, wherein said second promoter and said third promoter comprise an administered-compound-regulatable promoter wherein episomal replication occurs upon administration of a compound which interacts with said administered-compound-regulatable promoter and ceases upon cessation of administration of said compound. 9. The episomal vector system of claim 8 wherein said administered-compound-regulatable promoter transcriptionally linked to a nucleic acid is a steroid regulatable promoter and is activated by administration of a steroid hormone or steroid hormone analog. 10. The episomal vector system of claims 1-6 wherein said origin of replication, said vector maintenance sequence, said E1 sequence or said E2 sequence is from a Human papilloma virus. 11. The episomal vector system of claims 5-7 wherein said E1/E2 fusion gene sequence is a Human papilloma virus E1/E2 fusion gene sequence. 12. The episomal vector system of claims 1-6 wherein said origin of replication, said vector maintenance sequence, said E1 sequence or said E2 sequence is from a bovine papilloma virus. 13. The episomal vector system of claims 5-7 wherein said E1/E2 fusion gene sequence is a bovine papilloma virus E1/E2 fusion gene sequence. 14. The episomal vector system of claims 1-4 wherein said origin of replication, said E1 gene sequence and said E2 gene sequence are from a Human papilloma virus. 15. The episomal vector system of claims 1-4 wherein said origin of replication, said E1 gene sequence and said E2 gene sequence are from BPV-1. 16. The episomal vector system one of claims 5-7 wherein said origin of replication, and said E1/E2 fusion gene sequence are from BPV-1. 17. The episomal vector system of claims 1-4 wherein said origin of replication is selected from one type of papilloma virus, and said E1 gene is selected from the same type papilloma virus or another type papilloma virus, and said E2 gene is selected from the same type of papilloma virus as said origin of replication and for said E1 gene or a different type papilloma virus than one or both of the papilloma viruses from which said origin of replication and said E1 gene were selected. 18. The episomal vector system of claims 1-4 wherein said origin of replication is selected from one type of papilloma virus, and said E1 gene is selected from the same type papilloma virus or another type papilloma virus, and said E2 gene is selected from the same type of papilloma virus as said origin of replication or for said E1 gene or a different type papilloma virus than one or both of the papilloma viruses from which said origin of replication and said E1 gene were selected. 19. The episomal vector system of claims 5-7 wherein said origin of replication is selected from one type of papilloma virus, and said E1 gene sequence encoding the E1 portion of said E1/E2 fusion gene sequence is selected from the same type papilloma virus or another type papilloma virus, and said E2 gene sequence encoding the E2 portion of said E1/E2 fusion gene sequence is selected from the same type of papilloma virus as said origin of replication or for said E1 gene sequence or a different type papilloma virus than one or both of the papilloma viruses from which said origin of replication and said E1 gene sequence were selected. 20. The episomal vector system of claims 1-4 wherein one or more of said first, second and third promoters confer tissue-specific expression. 21. The episomal vector system of claim 20, wherein said promoters are tissue-specific promoters selected from the group consisting of: insulin promoter for pancreatic expression; creatine kinase promoter for skeletal muscle expression; immunoglobulin heavy chain promoter/enhancer for B-cell expression; albumin enhancer/promoter, tyrosine amino transferrin promoter, cytochrome P-450 promoter, apolipoprotein E promoter, apolipoprotein A-1 promoter and .beta.-actin promoter for liver expression; elastin, alpha-1 (I) collagen, keratin K1, K6 and loricrin for skin expression; alpha actin, beta myosin heavy chain, myosin light chain, aldolase A for muscle expression; type 4 collagenase, Clara protein, serine dehydratase for lung expression; myelin basic protein, beta amyloid precursor protein, glutamine synthetase, tyrosine hydroxylase for brain expression; globin, Immunoglobulin heavy and light chains for blood cell expression; and osteonectin, osteocalcin, osteopontin for bone expression. 22. The episomal vector system of claims 15 or 16 wherein said origin of replication is contained within a DNA sequence of about 3636 base pairs in length, and includes a nucleic acid sequence from Bovine papilloma virus type 1 from about nucleotide 6959 to 7945/1 and 7945/1 to about 471, wherein said Bovine papilloma virus type 1 nucleotide 7945/1 is within said origin of replication sequence of Bovine papilloma virus type 1. 23. The episomal vector system of claims 1-4 wherein both said second and third promoters are the same. 24. The episomal vector system of claim 23, wherein said promoters are an RSV-LTR. 25. The episomal vector system of claims 1-4 wherein said E1 and E2 gene sequences are a distance of at least about 1 Kb 5' and 3' from said origin of replication. 26. The episomal vector system of claims 5-7 wherein said E1/E2 fusion gene sequence is a distance of at least about 1 Kb 5' and 3' from said origin of replication. 27. The episomal vector system of claims 1-4 wherein said second and third promoters are albumin enhancer/promoters. 28. A method of producing a protein in vitro comprising the steps of introducing an episomal vector of claims 1-6 into a mammalian cell and expressing said DNA sequence such that production of said protein is detected. 29. The method of claim 28 wherein said DNA sequence is selected from the group consisting of nucleic acid sequences encoding enzymes, ligands, regulatory factors, and structural proteins. 30. The method of claim 28 wherein said DNA sequence is selected from the group consisting of nucleic acid sequences encoding nuclear proteins, cytoplasmic proteins mitochondrial proteins, secreted proteins, plasmallema-associated proteins, serum proteins, viral antigens, bacterial antigens, protozoal antigens and parasitic antigens. 31. The method of claim 28 wherein said DNA sequence is selected from the group consisting of nucleic acid sequences encoding proteins, lipoproteins, glycoproteins, phosphoproteins and nucleic acid. 32. The method of claim 28 wherein said DNA sequence is selected from the group consisting of nucleic acid sequences encoding hormones, growth factors, angiogenesis factors, matrix factors, enzymes, clotting factors, apolipoproteins, receptors, drugs, oncogenes, tumor antigens, tumor suppressors, viral antigens, parasitic antigens and bacterial antigens. 33. The method of claim 28 wherein the DNA sequence is selected from the group consisting of nucleic acid sequences encoding proinsulin, insulin, growth hormone, androgen receptors, insulin-like growth factor I, insulin-like growth factor II, insulin-like growth factor binding proteins, epidermal growth factor TGF-.alpha., TGF-.beta., PDGF, acidic fibroblast growth factor, basic fibroblast growth factor, angiogenin, Type IV collagen, Type VII collagen, laminin, phenylalanine hydroxylase, tyrosine hydroxylase, ras, fos, myc, erb, src, sis, jun, E6 transforming sequence, E7 transforming sequence, p53 protein Rb gene product, cytokine receptor, IL-1, IL-6, IL-8 and viral capsid protein. 34. A method for stably transforming a mammalian cell in vitro comprising the steps of introducing an episomal vector of claims 1-4 into said mammalian cell and expressing said E1 and E2 genes. 35. A method for stably transforming a mammalian cell in vitro comprising the steps of introducing an episomal vector of claims 5 or 6 into said mammalian cell and expression of said E1 and E2 genes. 36. A method for stably transforming a mammalian cell in vitro comprising the steps of introducing an episomal vector as in claim 7 into said mammalian cell and expression of said E1 and E2 genes. 37. A method for the in vitro regulation of an episomal vector replication comprising the steps of introducing to a mammalian cell an episomal vector of claim 8 and administering or ceasing to administer a compound which interacts with said administered-compound-regulatable promoter, wherein said E1 and E2 genes are expressed or ceases to be expressed. 38. A method causing cessation of production of a protein in vitro, comprising introducing to a mammalian cell an episomal vector of claim 1-6 wherein said DNA sequence encodes a protein which causes cell death thereby inhibiting production of said protein. 39. The method of claim 38, wherein said protein which causes cell death is thymidine kinase.

Details for Patent 5,674,703

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2014-10-07